<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04165226</url>
  </required_header>
  <id_info>
    <org_study_id>MMikhail</org_study_id>
    <nct_id>NCT04165226</nct_id>
  </id_info>
  <brief_title>LLLT and Fractional CO2 Laser in the Treatment of Stria Alba</brief_title>
  <official_title>Low Level Light Therapy and Fractional Carbon Dioxide Laser in the Treatment of Stria Alba: A Randomised Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stria alba (aka white or atrophic stretch marks) is a very common dermatologic condition that
      causes major psychological distress to those afflicted. We study the effect of low level
      light therapy using infra red diode 808/915 nm laser in comparison to fractional CO2 alone
      and combined both therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will be subjected to the following:

        -  Written informed consent.

        -  Detailed history and clinical evaluation.

      The treated areas will be photographed (in standardized settings of light and position) and
      measured in order to allow comparison and assessment of striae improvement following
      treatment.

      Patients will be allocated according to randomization into one of 3 arms:

      Arm A will be treated by fractional CO2 laser. Arm B will be treated by low level light
      therapy (LLLT). Arm C will be treated with a combination of fractional CO2 laser and LLLT.

      Digital photographs will be taken for each patient, at the baseline and 1 and 3 months after
      last session and the width of the widest striae in each patient will be measured at the same
      time. Patients will be assessed before and after treatment by one unblinded and 2 blinded
      investigators to measure the clinical improvement on a 4-point scale by comparing the
      photographs. The criteria for evaluation using a quartile grading scale will be as follows;
      0=no improvement, 1=mild improvement (&lt;25%), 2=moderate improvement (26% - 50%), 3=good
      improvement (51% -75%), 4=excellent improvement (&gt;76%).

      In addition, a patient satisfaction score will be rated using the following scale; 0=not
      satisfied, 1=slightly satisfied, 2= satisfied, 3=very satisfied, 4=extremely satisfied as
      well as patients' satisfaction questionnaire (Yang and Lee; 2011).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 24, 2018</start_date>
  <completion_date type="Actual">September 17, 2019</completion_date>
  <primary_completion_date type="Actual">September 17, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative effectiveness of the 3 intervention groups as assessed by patient global assessment at month 3 (End of study)</measure>
    <time_frame>3 months</time_frame>
    <description>Patients will be assessed before and after treatment by one unblinded and one blinded investigators to measure the clinical improvement on a 4-point scale by comparing the photographs. The criteria for evaluation using a quartile grading scale will be as follows; 0=no improvement, 1=mild improvement (&lt;25%), 2=moderate improvement (26% - 50%), 3=good improvement (51% -75%), 4=excellent improvement (&gt;76%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparative effectiveness of the 3 intervention groups as assessed by patient satisfaction score at month 3 (End of study)</measure>
    <time_frame>3 months</time_frame>
    <description>Patient satisfaction score will be rated using the following scale; 0=not satisfied, 1=slightly satisfied, 2= satisfied, 3=very satisfied, 4=extremely satisfied as well as patients' satisfaction questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparative effectiveness of the 3 intervention groups as assessed by physician global assessment at month 3 (End of study)</measure>
    <time_frame>3 months</time_frame>
    <description>Patients will be assessed before and after treatment by one unblinded and one blinded investigators to measure the clinical improvement on a 4-point scale by comparing the photographs. The criteria for evaluation using a quartile grading scale will be as follows; 0=no improvement, 1=mild improvement (&lt;25%), 2=moderate improvement (26% - 50%), 3=good improvement (51% -75%), 4=excellent improvement (&gt;76%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparative effectiveness of the 3 intervention groups as assessed by physician global assessment at month 1</measure>
    <time_frame>1 month</time_frame>
    <description>Patients will be assessed before and after treatment by one unblinded and one blinded investigators to measure the clinical improvement on a 4-point scale by comparing the photographs. The criteria for evaluation using a quartile grading scale will be as follows; 0=no improvement, 1=mild improvement (&lt;25%), 2=moderate improvement (26% - 50%), 3=good improvement (51% -75%), 4=excellent improvement (&gt;76%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative effectiveness of the 3 intervention groups as assessed by patient global assessment at month 1</measure>
    <time_frame>1 month</time_frame>
    <description>Patients will be assessed before and after treatment by one unblinded and one blinded investigators to measure the clinical improvement on a 4-point scale by comparing the photographs. The criteria for evaluation using a quartile grading scale will be as follows; 0=no improvement, 1=mild improvement (&lt;25%), 2=moderate improvement (26% - 50%), 3=good improvement (51% -75%), 4=excellent improvement (&gt;76%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative effectiveness of the 3 intervention groups as assessed by patient satisfaction score at month 1</measure>
    <time_frame>1 month</time_frame>
    <description>Patient satisfaction score will be rated using the following scale; 0=not satisfied, 1=slightly satisfied, 2= satisfied, 3=very satisfied, 4=extremely satisfied as well as patients' satisfaction questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative tolerability of the 3 intervention groups as assessed by the incidence of side effects (edema, pain, erythema, itching, peeling)</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of incidence of side effects (edema, pain, erythema, itching, start of peeling) in all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative tolerability of the fractional CO2 versus combined fractional and LLLT as regards duration of side effects in days after each laser session (edema, pain, erythema, itching, peeling)</measure>
    <time_frame>3 months</time_frame>
    <description>Comparative tolerability of the fractional CO2 versus combined fractional and LLLT as regards duration of side effects in days after each laser session (edema, pain, erythema, itching, peeling)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Striae; Albicantes</condition>
  <arm_group>
    <arm_group_label>Low level light therapy (LLLT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low level light therapy using 808/915 nm infra red diode laser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fractional CO2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fractional carbon dioxide laser 10600 nm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined fractional CO2 and LLLT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combined fractional CO2 laser and low level light therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low level light therapy</intervention_name>
    <description>Patients will be offered 8 sessions of photobiomodulation using HPL Pagani Diode 808/915nm LLLT 3.2W (Fimad Elettromedicali SRLÂ®, Catanzaro, Italy) with the parameters adjusted individually according to the surface area to be treated. Optimum dose is 10 joules/cubic centimeters. The patients will take 2 to3 sessions / week.</description>
    <arm_group_label>Low level light therapy (LLLT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fractional CO2</intervention_name>
    <description>Patients will be offered 2 sessions of fractional carbon dioxide laser on a 4 weeks interval. Topical anesthesia with pridocaine cream will be applied under occlusion for 30 - 60 minutes before the session.
Please update to the proper apparatus and parameters DEXA SmartXide DOT Fractional CO2 laser system 10600 nm (DEKAÂ®, Florence, Italy) will be used with the following parameters adjusted individually to patients': power of 15-20 W, dwell time of 500-800 Î¼s, spacing of 200-500 Î¼m, and stack 2.</description>
    <arm_group_label>Fractional CO2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Combined fractional CO2 laser and low level light therapy</intervention_name>
    <description>Combined treatment of both modalities (fractionational CO2 laser and low level light therapy). Please describe more....</description>
    <arm_group_label>Combined fractional CO2 and LLLT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects, above the age of 18 years old, with stria alba.

          -  Both genders.

        Exclusion Criteria:

          -  Pregnant or lactating females.

          -  Subjects who were treated with any interventional procedure (lasers, radiofrequency,
             dermabrasion, microdermabrasion, or chemical peeling) within 6 months prior to the
             study.

          -  Subjects who applied topical corticosteroids, retinoid, vitamin C, or vitamin E within
             3 months prior to the study.

          -  Subjects who orally took retinoids or corticosteroids within 3 months.

          -  Subjects who had a history of hypertrophic scar, keloid or immunosuppression or
             cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doaa Mahgoub, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vanessa Hafez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kasr El Ainy hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://www.fimadelettromedicali.it/site/index.php?option=com_content&amp;view=article&amp;id=80:laser-hpl-16-e-hpl-32-laser-ad-alta-potenza&amp;catid=62:elettrocardiografi-ecg&amp;Itemid=81</url>
    <description>Low level light therapy device</description>
  </link>
  <reference>
    <citation>Yang YJ, Lee GY. Treatment of Striae Distensae with Nonablative Fractional Laser versus Ablative CO(2) Fractional Laser: A Randomized Controlled Trial. Ann Dermatol. 2011 Nov;23(4):481-9. doi: 10.5021/ad.2011.23.4.481. Epub 2011 Nov 3.</citation>
    <PMID>22148016</PMID>
  </reference>
  <reference>
    <citation>Weiss, R. A., McDaniel, D. H., Geronemus, R. G., Weiss, M. A., Beasley, K. L., Munavalli, G. M., &amp; Bellew, S. G. (2005, September). Clinical experience with light-emitting diode (LED) photomodulation. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/16176771</citation>
  </reference>
  <reference>
    <citation>Hamblin, M. R. (2017, May 19). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28748217/</citation>
  </reference>
  <reference>
    <citation>Farivar S, Malekshahabi T, Shiari R. Biological effects of low level laser therapy. J Lasers Med Sci. 2014 Spring;5(2):58-62. Review.</citation>
    <PMID>25653800</PMID>
  </reference>
  <reference>
    <citation>Anders, J. J., Lanzafame, R. J., &amp; Arany, P. R. (2015, April 01). Clinical features and risk factors for striae distensae in Korean adolescents. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390214/</citation>
  </reference>
  <reference>
    <citation>K. Sawhney, Mossum &amp; Hamblin, Michael. (2014). Low-level light therapy (LLLT) for cosmetics and dermatology. Progress in Biomedical Optics and Imaging - Proceedings of SPIE. 8932. 10.1117/12.2041330.</citation>
  </reference>
  <reference>
    <citation>Aldahan AS, Shah VV, Mlacker S, Samarkandy S, Alsaidan M, Nouri K. Laser and Light Treatments for Striae Distensae: A Comprehensive Review of the Literature. Am J Clin Dermatol. 2016 Jun;17(3):239-56. doi: 10.1007/s40257-016-0182-8. Review.</citation>
    <PMID>26923916</PMID>
  </reference>
  <reference>
    <citation>Ross NA, Ho D, Fisher J, Mamalis A, Heilman E, Saedi N, Jagdeo J. Striae Distensae: Preventative and Therapeutic Modalities to Improve Aesthetic Appearance. Dermatol Surg. 2017 May;43(5):635-648. doi: 10.1097/DSS.0000000000001079. Review.</citation>
    <PMID>28375972</PMID>
  </reference>
  <reference>
    <citation>Mishra V, Miller L, Alsaad SM, Ross EV. The Use of a Fractional Ablative Micro-Plasma Radiofrequency Device in Treatment of Striae. J Drugs Dermatol. 2015 Nov;14(11):1205-8.</citation>
    <PMID>26580868</PMID>
  </reference>
  <reference>
    <citation>Ibrahim ZA, El-Tatawy RA, El-Samongy MA, Ali DA. Comparison between the efficacy and safety of platelet-rich plasma vs. microdermabrasion in the treatment of striae distensae: clinical and histopathological study. J Cosmet Dermatol. 2015 Dec;14(4):336-46. doi: 10.1111/jocd.12160. Epub 2015 Jul 6.</citation>
    <PMID>26147455</PMID>
  </reference>
  <reference>
    <citation>Mazzarello V, Farace F, Ena P, Fenu G, Mulas P, Piu L, Rubino C. A superficial texture analysis of 70% glycolic acid topical therapy and striae distensae. Plast Reconstr Surg. 2012 Mar;129(3):589e-590e. doi: 10.1097/PRS.0b013e3182419c40.</citation>
    <PMID>22374035</PMID>
  </reference>
  <reference>
    <citation>Ud-Din S, McAnelly SL, Bowring A, Whiteside S, Morris J, Chaudhry I, Bayat A. A double-blind controlled clinical trial assessing the effect of topical gels on striae distensae (stretch marks): a non-invasive imaging, morphological and immunohistochemical study. Arch Dermatol Res. 2013 Sep;305(7):603-17. doi: 10.1007/s00403-013-1336-7. Epub 2013 Apr 12.</citation>
    <PMID>23579949</PMID>
  </reference>
  <reference>
    <citation>Elson, M. (1994). Topical tretinoin in the treatment of striae distensae and in the promotion of wound healing: A review. Journal of Dermatological Treatment, 5(3), 163-165. doi:10.3109/09546639409084563</citation>
  </reference>
  <reference>
    <citation>Watson RE, Parry EJ, Humphries JD, Jones CJ, Polson DW, Kielty CM, Griffiths CE. Fibrillin microfibrils are reduced in skin exhibiting striae distensae. Br J Dermatol. 1998 Jun;138(6):931-7.</citation>
    <PMID>9747352</PMID>
  </reference>
  <reference>
    <citation>Lee KS, Rho YJ, Jang SI, Suh MH, Song JY. Decreased expression of collagen and fibronectin genes in striae distensae tissue. Clin Exp Dermatol. 1994 Jul;19(4):285-8.</citation>
    <PMID>7955466</PMID>
  </reference>
  <reference>
    <citation>Sheu HM, Yu HS, Chang CH. Mast cell degranulation and elastolysis in the early stage of striae distensae. J Cutan Pathol. 1991 Dec;18(6):410-6.</citation>
    <PMID>1774350</PMID>
  </reference>
  <reference>
    <citation>Gilmore SJ, Vaughan BL Jr, Madzvamuse A, Maini PK. A mechanochemical model of striae distensae. Math Biosci. 2012 Dec;240(2):141-7. doi: 10.1016/j.mbs.2012.06.007. Epub 2012 Jul 14.</citation>
    <PMID>22796062</PMID>
  </reference>
  <reference>
    <citation>Hague A, Bayat A. Therapeutic targets in the management of striae distensae: A systematic review. J Am Acad Dermatol. 2017 Sep;77(3):559-568.e18. doi: 10.1016/j.jaad.2017.02.048. Epub 2017 May 24. Review.</citation>
    <PMID>28551068</PMID>
  </reference>
  <reference>
    <citation>Cho S, Park ES, Lee DH, Li K, Chung JH. Clinical features and risk factors for striae distensae in Korean adolescents. J Eur Acad Dermatol Venereol. 2006 Oct;20(9):1108-13.</citation>
    <PMID>16987267</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Marina Mikhail</investigator_full_name>
    <investigator_title>Visiting resident</investigator_title>
  </responsible_party>
  <keyword>Stria alba</keyword>
  <keyword>Fractional CO2</keyword>
  <keyword>Fractional carbon dioxide laser 00</keyword>
  <keyword>Low level light therapy</keyword>
  <keyword>Striae atrophicae</keyword>
  <keyword>Infra red diode laser</keyword>
  <keyword>808 nm</keyword>
  <keyword>915 nm</keyword>
  <keyword>10600 nm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Striae Distensae</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD that underlie results in a publication, as well as protocol and statistical plan analysis, are to be published starting 6 months after the publication of summary data.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Starting 6 moths after publication of summary data</ipd_time_frame>
    <ipd_access_criteria>Data will be available for 6 months and allowed access only after approval of access requests by the principal investigators.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

